Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
160 participants
OBSERVATIONAL
2011-02-28
2012-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators hypothesize that analysis of VOCs in exhaled air of patients with liver diseases can be used for diagnosis and follow-up.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Volatile Organic Compounds for the Assessment of Liver Disease
NCT04620538
NASH: Non-invasive Diagnostic Markers and Imaging
NCT02717000
Prospective Cohort, With Biobanking, of Patients With Nonalcoholic Fatty Liver Disease
NCT02422238
Non-invasive Evaluation of Hepatic Fibrosis in Patients With the Metabolic Syndrome
NCT00399932
"Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and Chronic Liver Diseases".
NCT04690972
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with liver diseases of various etiologies
* viral hepatitis
* cholestatic liver diseases
* auto-immune hepatitis
* NAFLD
* ALD
* sarcoidosis of the liver
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age between 18 and 85 years
Exclusion Criteria
* Chronic obstructive lung disease, lung cancer, asthma
* Rheumatoid arthritis
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Maastricht University Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Maastricht University Medical Center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
A Masclee, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Maastricht University Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Maastricht University Medical Center, Division of Gastroenterology/Hepatology
Maastricht, Limburg, Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MEC 10-3-088
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.